Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is facing potential challenges due to rising operating costs and competition in the market, but their innovative Organ Care System (OCS) technology has the potential to greatly improve organ transplantation outcomes. Despite slower market growth and increased competition, TransMedics is expected to maintain adequate reimbursement and potentially gain a larger share in the OCS market. Surgeons have shown mixed views on the company's next-generation OCS and ELATE study, but remain generally optimistic about its potential. However, TransMedics will need to carefully manage expenses and address any concerns from surgeons to achieve success in the organ transplantation market.

Bears say

TransMedics Group is facing challenges in the organ transplant market but remains confident in the potential of their technology and upcoming catalysts. However, its financial performance has been impacted by acquisitions and it may face further challenges from CMS initiatives and competition in the OPO market. These factors, combined with a potential overestimation of potential revenue, contribute to a negative outlook on the company's stock.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $120.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $120.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.